keyword
MENU ▼
Read by QxMD icon Read
search

stereotactic ablative radiotherapy

keyword
https://www.readbyqxmd.com/read/28636530/gamma-analysis-with-a-gamma-criterion-of-2-1-mm-for-stereotactic-ablative-radiotherapy-delivered-with-volumetric-modulated-arc-therapy-technique-a-single-institution-experience
#1
Jung-In Kim, Minsoo Chun, Hong-Gyun Wu, Eui Kyu Chie, Hak Jae Kim, Jin Ho Kim, Jong Min Park
To report a single-institution experience of gamma evaluations with 2%/1 mm for stereotactic ablative radiotherapy (SABR) delivered with volumetric modulated arc therapy (VMAT) technique, from January 2014 to January 2016. A total of 168 SABR VMAT plans were analyzed with a gamma criterion of 2%/1 mm, a threshold value of 10%, and a tolerance level of 90%. Of the 168 cases, four cases failed with 2%/1 mm. The average passing rate was 97.0% ± 2.5%. Three of the four failed cases showed passing rates higher than 90%, which was achieved by shifting the measuring device by 1 mm in the left-to-right or anterior-to-posterior directions...
June 16, 2017: Oncotarget
https://www.readbyqxmd.com/read/28631740/radiotherapy-for-renal-cell-carcinoma-renaissance-of-an-overlooked-approach
#2
REVIEW
Shankar Siva, Gargi Kothari, Alexander Muacevic, Alexander V Louie, Ben J Slotman, Bin S Teh, Simon S Lo
Conventional radiotherapy previously had a limited role in the definitive treatment of renal cell carcinoma (RCC), owing to the disappointing outcomes of several trials and the perceived radioresistance of this type of cancer. In this context, radiotherapy has been relegated largely to the palliation of symptoms in patients with metastatic disease, with variable rates of response. Following the availability of newer technologies that enable safe delivery of high-dose radiotherapy, stereotactic ablative radiotherapy (SABR) has become increasingly used in patients with RCC...
June 20, 2017: Nature Reviews. Urology
https://www.readbyqxmd.com/read/28616316/what-is-the-role-of-stereotactic-ablative-radiotherapy-in-the-management-of-surgically-resectable-and-operable-stage-i-non-small-cell-lung-cancer
#3
EDITORIAL
Susannah M Love, Gillian Hardman, Ruchir Mashar, Rajesh D Shah
No abstract text is available yet for this article.
May 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28605745/current-standard-and-future-perspectives-in-non-surgical-therapy-for-hepatocellular-carcinoma
#4
Tobias Eggert, Tim F Greten
BACKGROUND: Hepatocellular carcinoma (HCC) is an aggressive liver tumor with a poor 5-year survival rate. Many HCCs are not amenable to surgical resection, because of tumor size, location, or because of the patient's poor liver function, a common obstacle to HCC therapy, because HCCs almost always develop in chronically inflamed livers. SUMMARY: In recent years, many efforts have been made to improve patient survival by conducting clinical trials investigating local and systemic treatment options for patients with unresectable tumors...
June 13, 2017: Digestion
https://www.readbyqxmd.com/read/28592286/immunological-effect-of-local-ablation-combined-with-immunotherapy-on-solid-malignancies
#5
REVIEW
Yusuke Takahashi, Noriyuki Matsutani, Takashi Nakayama, Hitoshi Dejima, Hirofumi Uehara, Masafumi Kawamura
Recent comprehensive investigations clarified that immune microenvironment surrounding tumor cells are deeply involved in tumor progression, metastasis, and response to treatment. Furthermore, several immunotherapeutic trials have achieved successful results, and the immunotherapeutic agents are available in clinical practice. To enhance their demonstrated efficacy, combination of immunotherapy and ablation has begun to emerge. Local ablations have considerable advantages as an alternative therapeutic option, especially its minimal invasiveness...
June 7, 2017: Chinese Journal of Cancer
https://www.readbyqxmd.com/read/28590814/a-dosimetric-parameter-to-limit-chest-wall-toxicity-in-sabr-of-nsclc
#6
Raphaël Jumeau, Édith Filion, Houda Bahig, Toni Vu, Louise Lambert, David Roberge, Robert Doucet, Marie-Pierre Campeau
OBJECTIVE: Chest wall (CW) toxicity (rib fracture and/or pain) is a recognized complication of stereotactic ablative radiotherapy (SABR) for non-small cell lung cancer (NSCLC). The aim of this study was to evaluate the frequency of CW toxicity following SABR and to propose a new dosimetric parameter. METHODS: We reviewed the charts and SABR plans from patients treated for T1-T2N0 peripheral NSCLC between 2009 and 2015. The CW structure was created through a 3 cm expansion of the lung...
June 7, 2017: British Journal of Radiology
https://www.readbyqxmd.com/read/28581406/long-term-survival-analysis-of-stereotactic-ablative-radiotherapy-versus-liver-resection-for-small-hepatocellular-carcinoma
#7
Ting-Shi Su, Ping Liang, Jian Liang, Huan-Zhen Lu, Hua-Yan Jiang, Tao Cheng, Yong Huang, Yang Tang, Xin Deng
PURPOSE: To compare the efficacy of stereotactic ablative radiation therapy (SABR) versus liver resection for small hepatocellular carcinoma (HCC) ≤5 cm with Child-Pugh A cirrhosis. METHODS AND MATERIALS: This retrospective study included 117 patients with small HCCs with 1 or 2 nodules. Eighty-two patients received SABR (SABR group), and 35 patients underwent liver resection (resection group). Overall survival (OS) and progression-free survival (PFS) were analyzed...
July 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28577830/stereotactic-ablative-body-radiotherapy-for-lung-metastases-where-is-the-evidence-and-what-are-we-doing-with-it
#8
REVIEW
Shankar Siva, Ben J Slotman
This review provides an overview of the use of stereotactic ablative body radiotherapy (SABR) for pulmonary metastases. The local control rates after SABR are generally >90%. Whether this also translates into a significant improvement in overall survival is the subject of ongoing studies. New exciting opportunities including the integration of SABR with targeted and immune therapies as well as some competing treatment strategies are discussed.
July 2017: Seminars in Radiation Oncology
https://www.readbyqxmd.com/read/28577829/stereotactic-ablative-radiotherapy-for-early-stage-lung-cancer
#9
REVIEW
Jennifer L Shah, Billy W Loo
The rising incidence of early-stage lung cancer, particularly in medically inoperable patients, is anticipated because of the implementation of early detection strategies and population aging in the United States and worldwide. This mandates the development of noninvasive curative treatment approaches for this disease. Stereotactic ablative radiotherapy (SABR) has recently emerged as a standard of care for early-stage lung cancer in medically inoperable patients who cannot safely tolerate surgical lobectomy, the established standard for operable patients...
July 2017: Seminars in Radiation Oncology
https://www.readbyqxmd.com/read/28577828/stereotactic-body-radiotherapy-in-the-treatment-of-spinal-metastases
#10
REVIEW
Evangelia Katsoulakis, Kiran Kumar, Ilya Laufer, Yoshiya Yamada
Patients with metastatic disease including polymetastatic, oligometastatic, and oligorecurrent spinal lesions have extended life expectancy secondary to improvements in systemic agents, and thus require durable local control of spine metastases. Stereotactic body radiotherapy (SBRT), which uses highly conformal treatment planning techniques coupled with image-guided technology, has enabled the safe delivery of tumor-ablative doses of radiotherapy. The NOMS decision framework has been developed as a tool to aid in the determination of the optimal treatment of spinal metastases, incorporating radiosurgery, separation surgery, stabilization techniques, and conventional radiation...
July 2017: Seminars in Radiation Oncology
https://www.readbyqxmd.com/read/28577827/normal-tissue-constraints-for-abdominal-and-thoracic-stereotactic-body-radiotherapy
#11
REVIEW
Erqi L Pollom, Alexander L Chin, Maximilian Diehn, Billy W Loo, Daniel T Chang
Although stereotactic body radiotherapy (SBRT) or stereotactic ablative radiotherapy has become an established standard of care for the treatment of a variety of malignancies, our understanding of normal tissue dose tolerance with extreme hypofractionation remains immature. Since Timmerman initially proposed normal tissue dose constraints for SBRT in the 2008 issue of Seminars of Radiation Oncology, experience with SBRT has grown, and more long-term clinical outcome data have been reported. This article reviews the modern toxicity literature and provides updated clinically practical and useful recommendations of SBRT dose constraints for extracranial sites...
July 2017: Seminars in Radiation Oncology
https://www.readbyqxmd.com/read/28576747/brief-report-long-term-outcome-of-surgery-or-stereotactic-radiotherapy-for-lung-oligometastases
#12
Joyce E Lodeweges, Theo J Klinkenberg, Jan F Ubbels, Harry J M Groen, Johannes A Langendijk, Joachim Widder
Local treatment for pulmonary oligometastases (one to five lesions) employing metastasectomy or stereotactic ablative radiotherapy (SABR) was investigated in a cohort having received multidisciplinary tumour-board-based treatment decisions. First choice of treatment was surgery, SABR was recommended in case of clinical adverse factors. Propensity-score adjusted and unadjusted overall survival (OS) was the primary endpoint, local control and time-to-failure of a local-only treatment strategy were also analysed...
May 30, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28550029/pulmonary-function-changes-after-radiotherapy-for-lung-or-esophageal-cancer-a-systematic-review-focusing-on-dose-volume-parameters
#13
Anne G H Niezink, Renske A de Jong, Christina T Muijs, Johannes A Langendijk, Joachim Widder
BACKGROUND: Despite technical developments in treatment delivery, radiation-induced lung toxicity (RILT) remains a crucial problem in thoracic radiotherapy. Clinically based RILT scores have their limitations, and more objective measures such as pulmonary functions tests (PFTs) might help to improve treatment strategies. PURPOSE: To summarize the available evidence about the effect of dose to the lung in thoracic radiotherapy on forced expiratory volume in one second (FEV1) and diffusion capacity (DLCO) in patients with lung and esophageal cancer treated with curative intent...
May 26, 2017: Oncologist
https://www.readbyqxmd.com/read/28545199/cyberknife-radioablation-of-prostate-cancer-%C3%A2-preliminary-results-for-400-patients
#14
Leszek Miszczyk, Agnieszka Namysł Kaletka, Aleksandra Napieralska, Grzegorz Woźniak, Małgorzata Stąpór Fudzińska, Grzegorz Głowacki, Andrzej Tukiendorf
Objectives: To evaluate the tolerance and effectiveness of stereotactic ablative radiotherapy (SABR) applied in the treatment of low and intermediate risk (LR & IR) prostate cancer patients (PCP) and provide an evaluation of the level of risk group impact on treatment results. In addition, androgen deprivation therapy (ADT) usage and prostatic specific antigen (PSA) decline after SABR were assessed. Material and Methods: A total of 400 PCP (213 LR and 187 IR, including T2c) were irradiated with a CyberKnife using fd 7...
April 1, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/28545098/survival-and-prognostic-factors-for-patients-with-advanced-hepatocellular-carcinoma-after-stereotactic-ablative-radiotherapy
#15
Cheng-Hsiang Lo, Jen-Fu Yang, Ming-Yueh Liu, Yee-Min Jen, Chun-Shu Lin, Hsing-Lung Chao, Wen-Yen Huang
OBJECTIVE: To evaluate the survival outcomes and prognostic factors of patients with advanced hepatocellular carcinoma (HCC) who underwent stereotactic ablative radiotherapy (SABR). METHODS: This retrospective study evaluated patients with advanced HCC who underwent SABR between December 2007 and July 2015. All patients had Barcelona Clinic Liver Cancer stage C disease and Child-Turcotte-Pugh (CTP) class A-B function. In-field control (IFC), overall survival (OS), prognostic factors, and toxicity were evaluated...
2017: PloS One
https://www.readbyqxmd.com/read/28535921/out-of-field-in-vivo-dosimetry-using-tld-in-sabr-for-primary-kidney-cancer-involving-mixed-photon-fields
#16
P Lonski, S Keehan, S Siva, D Pham, R D Franich, M L Taylor, T Kron
PURPOSE: To assess out-of-field dose using three different variants of LiF thermoluminescence dosimeters (TLD) for ten patients who underwent stereotactic ablative body radiotherapy (SABR) for primary renal cell carcinoma (RCC) and compare with treatment planning system (TPS) dose calculations. METHODS AND MATERIALS: Thermoluminescent dosimeter (TLD) measurements were conducted at 20, 30, 40 and 50cm from isocentre on ten patients undergoing SABR for primary RCC...
May 2017: Physica Medica: PM
https://www.readbyqxmd.com/read/28532400/oligometastases-from-prostate-cancer-local-treatment-with-stereotactic-body-radiotherapy-sbrt
#17
Gregor Habl, Christoph Straube, Kilian Schiller, Marciana Nona Duma, Markus Oechsner, Kerstin A Kessel, Matthias Eiber, Markus Schwaiger, Hubert Kübler, Jürgen E Gschwend, Stephanie E Combs
BACKGROUND: The impact of local tumor ablative therapy in oligometastasized prostate cancer (PC) is still under debate. To gain data for this approach, we evaluated oligometastasized PC patients receiving stereotactic body radiotherapy (SBRT) to bone metastases. METHODS: In this retrospective study, 15 oligometastasized PC patients with a total of 20 bone metastases were evaluated regarding biochemical progression-free survival (PSA-PFS), time to initiation of ADT, and local control rate (LCR)...
May 22, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28530067/-stereotactic-ablative-body-radiation-sabr-a-new-therapeutic-option-for-treatment-of-stage-i-lung-cancer
#18
REVIEW
Sarit Appel, Zvi Symon
Stereotactic ablative radiotherapy (SABR) also known as stereotactic body radiation therapy (SBRT) offers a new therapeutic option for stage 1 lung cancer that cannot undergo surgery due to co-morbidities or patient refusal. This treatment evolved in the last decade thanks to technologic advancement of radiation therapy planning and delivery that allow real time imaging of the tumor and real time position correction before every treatment. Ultra high doses of radiation cause ablation of the target with very low collateral scatter dose to surrounding tissue...
November 2016: Harefuah
https://www.readbyqxmd.com/read/28526616/stereotactic-ablative-radiotherapy-in-treatment-of-early-stage-non-small-cell-lung-cancer-unsolved-questions-and-frontiers-ahead
#19
Jingze Zhang, Li Kong, Qinghua Jiao, Minghuan Li, Jingming Yu
Stereotactic ablative radiotherapy (SABR) has been recognized as a standard alternative treatment to surgery for inoperable early stage non-small cell lung cancer (NSCLC). Guaranteed local control rates over 90% makes oncologists wonder whether SABR is qualified enough to challenge surgery in operable patients. The role of SABR for centrally located lesions would be another question because of the increased risk of severe toxic effect. Plenty of studies suggest that optimization of dose regimen and appropriate case selection would be helpful...
May 16, 2017: Cancer Letters
https://www.readbyqxmd.com/read/28507888/spine-stereotactic-body-radiotherapy-indications-outcomes-and-points-of-caution
#20
Chia-Lin Tseng, Wietse Eppinga, Raphaele Charest-Morin, Hany Soliman, Sten Myrehaug, Pejman Jabehdar Maralani, Mikki Campbell, Young K Lee, Charles Fisher, Michael G Fehlings, Eric L Chang, Simon S Lo, Arjun Sahgal
STUDY DESIGN: A broad narrative review. OBJECTIVES: The objective of this article is to provide a technical review of spine stereotactic body radiotherapy (SBRT) planning and delivery, indications for treatment, outcomes, complications, and the challenges of response assessment. The surgical approach to spinal metastases is discussed with an overview of emerging minimally invasive techniques. METHODS: A comprehensive review of the literature was conducted on the techniques, outcomes, and developments in SBRT and surgery for spinal metastases...
April 2017: Global Spine Journal
keyword
keyword
42615
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"